ICYMI, this week we had stories on infectious diseases, new drug approvals, and more.
Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference.
What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.
Sunscreen advice, recruiting during the “Great Recession”, and tips for the office led the busy agenda at Winter Clinical Dermatology Conference this weekend.
Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.
A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.
A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.
As skin manifestations are commonly the first thing spotted with infectious disease, dermatologists are in a great position to counsel patients about prevention.
More trustworthy sources of information, and data, are needed.
AbbVie announces the approval after 3 studies show the efficacy and safety of upadacitinib using mono- and combination therapy.
Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.
Resident billing can have huge financial implications on academic institutions. A poster from the Icahn School of Medicine at Mount Sinai aimed to assess new medical coding lectures and a modified note template at Winter Clinical Dermatology Conference.
Targeting skin care regimens to the individual patient is most likely to yield compliance to a recommended routine.
The FDA has approved abrocitinib for adult patients with moderate to severe AD.
AAD vice president challenges dermatologists to advocate for their patients and themselves.
One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.
Treating these patients can be a challenge, but it can also be ‘as easy as pie’ if you follow these tips.
The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.
Vial announced an advisory board to discuss dermatology CROs at the 2022 Winter Clinical Dermatology Conference.
Dermavant had patient satisfaction data from the PSOARING 3 long term extension trial presented at the 2022 Winter Clinical Dermatology Conference.
Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.
In this week’s Pointers with Dr Portela, the 208SkinDoc dives into a social media video that shows someone advocating for urine for hair, skin, and overall body care. See what he has to say about this.
A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.
A research letter published by the Journal of the American Academy of Dermatology dove into the question of how psoriasis may increase the overall risk of cutaneous malignant melanoma in patients.
Will Kirby, DO, FAOCD, board-certified dermatologist, chief medical officer of LaserAway, and Dermatology Times® editorial board member, will be speaking at the Medical Spa Show, presented by the American Med Spa Association.
Clinicians need to avoid negative terms in describing patients.
With increased infectivity of Omicron, the Centers for Control and Prevention (CDC) has updated the guidance on the best mask types to use.